Picture of Power: Price Momentum Map Syntax

Stephen Stewart Author is a PRO memberHas Had Over 300 FollowersJust earned! - Has Been a Top Public ChartList for Over 2 years Rank: 5 Followers: 394 Votes: 415 Years Member: 8 Last Update: 29 August 2014, 18:45 Categories: Momentum Stocks

WebSite

Trade what you see, not what you think. Train the Eye. Optimize the 'sweet spot' of price action.

*************************************************************
'MAP SYNTAX', is a 'Performance Driven' Discretionary (vs. Black Box) proprietary research effort that focuses on finding the
best stocks the market has to offer. Using multiple time frames, 'MAP SYNTAX' is designed to identify the best candidates for
both long term price momentum investing and short term price 'thrusts' for swing trading. Optimize the 'Sweet Spot'.

All charts are strictly for educational purposes only. No investment decisions should be made based on the analysis here.
Momentum investing can lead to large losses. Very important to have a sound money management strategy.

Map Syntax & Stephen Stewart are not a registered investment adviser, investment advisory service, registered analyst,
or broker-dealer and does not advise specific advice on securities to anyone.

Less

$.....Map Syntax

In Map Syntax land, we care about 'VIOLENT' price action and optimizing it. Thats it. Simple Simon

00/00 (Bias)

08/27: (Long Bias) TUBE
08/26: (Long Bias) MOBL
08/23: (Long Bias) CDZI
--------------------------
Price action goes into Map Syntax, answers come out. Listen to your MAPS.

When you master your craft (trading system) and can execute flawlessly - There is a price you pay - Work (trading) becomes boring.
However, the financial rewards become astronomical, just ask Tiger Woods or Roger Federer. ....And when you ask them how
they MASTERED THEIR 'CRAFT', they will tell you, it isnt the mechanics or system of their game that takes them to the top, but rather,
the six inches of space between their ears that they have learned to manage and master. Trading is no different. ~

1.1a1 TASR - Case Study - `Model Analysis`

In my opinion, trading momentum is for the investor that wants to get paid right now. It is nothing more then participating in a trend. However,
momentum investing is 'NOT' a good 'risk/reward' trade. In fact it is risky because you are betting on other investors to keep buying in the face
of higher prices by chasing prices. We are trying to profit from investors' fear of 'MISSING THE MOVE'. However, you can manage this
risk well. How? Because you can always sell (if your wrong).

1.1b ......................................aaaaaaaaa GPRO - 20.47m Float.

In 2011, 2012, 2013 and the three months ended March 31, 2014, GPRO generated revenue of $234.2 million, $526.0 million, $985.7 million
and $235.7 million and reported net income of $24.6 million, $32.3 million, $60.6 million and $11.0 million, respectively.
To date, substantially all of our revenue has been generated from the sale of our capture devices. (Source: IPO Prospectus)

1.1b .....................................aaaaaa MBLY - Driverless Car Technology - 35.6m Float

1.1b ...................................aaaaaaaaaaaaaaaa MOBL - 11m Float

1.1b ................................aaaaaaaaa TRUE - 7.8m Float

TRUE is a pure play on US Auto Sales (New & Used). If US Auto sales rise/accelerate each month, its a TAILWIND for TRUE and its stock $.
Monthly US Auto sales are released the first week of each month. Keep that in mind because if traders want to bet on a BULLISH report, they
will likely MARK-UP the stock price of TRUE in anticipation of the report. [Charts are the primary window to $ optimization; but when you can
weave in the anticipation of fundamental metrics - company or industry specific - a trader can really increase his market timing capabilities.]

1.1b ...............................aaaaaa AGRX - 9.2m Float

6/20: Outperform at William Blair (7.48 +0.70): William Blair initiated AGRX with a Outperform; firm derived NPV for co's lead product, a
contraceptive patch called Twirla that is entering a Phase III study, of about $18/share. Co is conducting the current Phase III study for
Twirla following a negative FDA review of the initial new drug application in 2013. Firm believes the first Phase III study for Twirla,
while suggesting efficacy, had many flaws stemming from study design, enrollment, and conduct. However, firm has confidence in co's
new clinical leadership and believe that this setback provided an entry point for investors in what it views as a relatively low-risk Phase III product.

1.1b ...............................aaaaaaaa TUBE - 6.3m Float

1.1b .....................aaaaaaaa TTOO - 5.2m Float

Sepsis is an illness in which the body has a severe, inflammatory response to a bacterial or fungal infection. It is a life-threatening condition to
which individuals with weakened immune systems or chronic illnesses are highly susceptible. Sepsis can lead to shock and organ failure, and is
a leading cause of death in the United States with a mortality rate of approximately 30%, almost double the mortality rate of acute myocardial
infarction, or heart attack. Over 1.6 million individuals are diagnosed with sepsis each year, 1.35 million of whom are at high risk for infection due
to their suppressed immune system or their presence in critical care units. In 2013, the U.S. Department of Health and Human Services reported
that sepsis is the most expensive hospital-treated condition in the United States, with an economic burden to hospitals exceeding $20 billion annually.

1.1c. CIRCLES OF STIMULUS - Market Timing & Price Optimization.

Two times a day, Wall street delivers THRUST, BUST or STALL.
Use those KEY DECISION TIMES to identify and time THRUST as well as pick an ideal time to book gains or cut losses.
[NOTE: This is not day trading.]

MONEY MGMT = Position Size, Timing the Entry, Cutting Losses & Booking Gains

This information is presented for education purposes only. StockCharts.com is not responsible for any comments, advice, or annotations presented on this page. Please review our Terms of Use for more details.